Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

These days, many devices are programmed through apps on patients’ phones. But the FDA warns that certain phone settings, such ...

Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even before symptoms occur.

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...

Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can predict microvascular diabetes complications similarly to glycated hemoglobin.

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...

Shanghai's Ruijin Hospital announced today that researchers have developed a groundbreaking non-invasive blood glucose ...

Shanghai researchers have devised a revolutionary, non-invasive method to monitor blood glucose, allowing for accurate blood ...

Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...

The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for ...

Discover how the first FDA-approved over-the-counter continuous glucose monitor affects the wellness industry and its potential for early diabetes diagnoses.

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...